534 related articles for article (PubMed ID: 30417487)
1. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
Ali S; AlThubaiti S; Renzi S; Krueger J; Chiang KY; Naqvi A; Schechter T; Punnett A; Ali M
Pediatr Transplant; 2019 Feb; 23(1):e13319. PubMed ID: 30417487
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic stem-cell transplantation for adult and adolescent hemophagocytic lymphohistiocytosis: a single center analysis.
Fu L; Wang J; Wei N; Wu L; Wang Y; Huang W; Zhang J; Liu J; Wang Z
Int J Hematol; 2016 Nov; 104(5):628-635. PubMed ID: 27431489
[TBL] [Abstract][Full Text] [Related]
3. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan.
Ohga S; Kudo K; Ishii E; Honjo S; Morimoto A; Osugi Y; Sawada A; Inoue M; Tabuchi K; Suzuki N; Ishida Y; Imashuku S; Kato S; Hara T
Pediatr Blood Cancer; 2010 Feb; 54(2):299-306. PubMed ID: 19827139
[TBL] [Abstract][Full Text] [Related]
5. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
6. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Imadome KI; Mizukami Y; Okumura T
Medicine (Baltimore); 2022 Mar; 101(12):e29055. PubMed ID: 35357349
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
Sato E; Ohga S; Kuroda H; Yoshiba F; Nishimura M; Nagasawa M; Inoue M; Kawa K
Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
[TBL] [Abstract][Full Text] [Related]
8. [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].
Xu LP; Huang XJ; Liu DH; Chen YH; Shi HX; Chen DB
Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):996-9. PubMed ID: 18478915
[TBL] [Abstract][Full Text] [Related]
9. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
11. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
Yamamoto N; Nishimura N; Takeuchi M; Ito T; Yokozaki H; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Nishio H; Matsuo M; Imadome K; Iijima K
Eur J Pediatr; 2014 Dec; 173(12):1615-8. PubMed ID: 24169729
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Romero S; Montoro J; Guinot M; Almenar L; Andreu R; Balaguer A; Beneyto I; Espí J; Gómez-Codina J; Iacoboni G; Jarque I; López-Andújar R; Mayordomo-Aranda E; Montalar J; Pastor A; Pastor M; Piñana JL; Rojas-Ferrer N; Sánchez-Lázaro I; Sandoval J; Sanz G; Sanz MÁ; Solé A; Sanz J
Leuk Lymphoma; 2019 Jan; 60(1):142-150. PubMed ID: 29966464
[TBL] [Abstract][Full Text] [Related]
13. [The clinical characteristics of adult hemophagocytic lymphohistiocytosis treated with haploidentical donor hematopoietic stem cell transplantation].
Fu L; Wei N; Wang JS; Wu L; Wang YN; Huang DY; Liu JL; Wang Z
Zhonghua Nei Ke Za Zhi; 2017 Apr; 56(4):273-278. PubMed ID: 28355720
[No Abstract] [Full Text] [Related]
14. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
[TBL] [Abstract][Full Text] [Related]
15. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T
Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
[TBL] [Abstract][Full Text] [Related]
16. [The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
Niu YY; Dong YJ; Yin Y; Xu WL; Liang ZY; Wang Q; Li Y; Liu W; Ou JP; Ren HY
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):904-910. PubMed ID: 35045651
[No Abstract] [Full Text] [Related]
17. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
Naik S; Riches M; Hari P; Kim S; Chen M; Bachier C; Shaughnessy P; Hill J; Ljungman P; Battiwalla M; Chhabra S; Daly A; Storek J; Ustun C; Diaz MA; Cerny J; Beitinjaneh A; Yared J; Brown V; Page K; Dahi PB; Ganguly S; Seo S; Chao N; Freytes CO; Saad A; Savani BN; Woo Ahn K; Boeckh M; Heslop HE; Lazarus HM; Auletta JJ; Kamble RT
Transpl Infect Dis; 2019 Oct; 21(5):e13145. PubMed ID: 31301099
[TBL] [Abstract][Full Text] [Related]
18. [Dynamic monitoring of plasma Epstein-Barr Virus DNA load can predict the occurrence of lymphoproliferative disorders after haploidentical hematopoietic stem cell transplantation].
Chen J; Sun YQ; Xu LP; Zhang XH; Liu KY; Mo XD; Cheng YF; Huang XJ; Wang Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):284-288. PubMed ID: 37356996
[No Abstract] [Full Text] [Related]
19. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.
Chen DB; Song QJ; Chen YX; Chen YH; Shen DH
Int J Hematol; 2013 Jan; 97(1):117-24. PubMed ID: 23255160
[TBL] [Abstract][Full Text] [Related]
20. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
